Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Patrick Gregory Gavin, Ph.D.

Title
Institution
Department
Address
Phone

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Gavin PG, Wong J, Loo D, Zipris D, Hill MM, Hamilton-Williams EE. Metaproteomic sample preparation methods bias the recovery of host and microbial proteins according to taxa and cellular compartment. J Proteomics. 2021 May 30; 240:104219. PMID: 33831598.
    Citations:    Fields:    
  2. Yap YA, McLeod KH, McKenzie CI, Gavin PG, Davalos-Salas M, Richards JL, Moore RJ, Lockett TJ, Clarke JM, Eng VV, Pearson JS, Hamilton-Williams EE, Mackay CR, Mariño E. An acetate-yielding diet imprints an immune and anti-microbial programme against enteric infection. Clin Transl Immunology. 2021; 10(1):e1233. PMID: 33489123.
    Citations:    
  3. Jacobs SA, Lee JJ, George TJ, Wade JL, Stella PJ, Wang D, Sama AR, Piette F, Pogue-Geile KL, Kim RS, Gavin PG, Lipchik C, Feng H, Wang Y, Finnigan M, Kiesel BF, Beumer JH, Wolmark N, Lucas PC, Allegra CJ, Srinivasan A. Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study. Clin Cancer Res. 2021 Mar 15; 27(6):1612-1622. PMID: 33203645.
    Citations:    Fields:    
  4. Pogue-Geile KL, Song N, Serie DJ, Wang Y, Gavin PG, Kim RS, Tanaka N, Fumagalli D, Taniyama Y, Li Z, Rastogi P, Swain SM, Mamounas EP, Geyer CE, Wolmark N, Lucas PC, Paik S, Thompson EA. Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831. JNCI Cancer Spectr. 2020 Oct; 4(5):pkaa058. PMID: 33241186.
    Citations:    
  5. Jacobs SA, Robidoux A, Abraham J, Pérez-Garcia JM, La Verde N, Orcutt JM, Cazzaniga ME, Piette F, Antolín S, Aguirre E, Cortes J, Llombart-Cussac A, Di Cosimo S, Kim RS, Feng H, Lipchik C, Lucas PC, Srinivasan A, Wang Y, Song N, Gavin PG, Balousek AD, Paik S, Allegra CJ, Wolmark N, Pogue-Geile KL. Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer. Breast Cancer Res. 2020 Jan 22; 22(1):9. PMID: 31969184.
    Citations:    Fields:    
  6. Jacobs SA, Robidoux A, Abraham J, Pérez-Garcia JM, La Verde N, Orcutt JM, Cazzaniga ME, Piette F, Antolín S, Aguirre E, Cortes J, Llombart-Cussac A, Di Cosimo S, Kim RS, Feng H, Lipchik C, Lucas PC, Srinivasan A, Wang Y, Song N, Gavin PG, Balousek AD, Paik S, Allegra CJ, Wolmark N, Pogue-Geile KL. NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer. Breast Cancer Res. 2019 12 03; 21(1):133. PMID: 31796073.
    Citations: 4     Fields:    
  7. Chumsri S, Li Z, Serie DJ, Mashadi-Hossein A, Colon-Otero G, Song N, Pogue-Geile KL, Gavin PG, Paik S, Moreno-Aspitia A, Perez EA, Thompson EA. Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31. J Clin Oncol. 2019 12 10; 37(35):3425-3435. PMID: 31622131.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  8. Lowenstein LM, Volk RJ, Cuddy A, Hempstead AP, You YN, Van Loon K, Millas S, Meyerhardt JA, Gavin P, Chang GJ. Patients' information needs and attitudes about post-treatment surveillance for colorectal cancer in the United States: a multi-perspective, mixed methods study. BMJ Open. 2019 08 15; 9(8):e025888. PMID: 31420381.
    Citations: 1     Fields:    Translation:Humans
  9. Gavin PG, Hamilton-Williams EE. The gut microbiota in type 1 diabetes: friend or foe? Curr Opin Endocrinol Diabetes Obes. 2019 08; 26(4):207-212. PMID: 31145129.
    Citations: 5     Fields:    Translation:HumansAnimals
  10. Kim RS, Song N, Gavin PG, Salgado R, Bandos H, Kos Z, Floris G, Eynden GGGMVD, Badve S, Demaria S, Rastogi P, Fehrenbacher L, Mamounas EP, Swain SM, Wickerham DL, Costantino JP, Paik S, Wolmark N, Geyer CE, Lucas PC, Pogue-Geile KL. Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer. J Natl Cancer Inst. 2019 08 01; 111(8):867-871. PMID: 30888406.
    Citations: 6     Fields:    Translation:HumansCells
  11. Pal R, Wei N, Song N, Wu S, Kim RS, Wang Y, Gavin PG, Lucas PC, Srinivasan A, Allegra CJ, Jacobs SA, Paik S, Schmitz JC, Pogue-Geile KL. Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations. PLoS One. 2018; 13(8):e0200836. PMID: 30118499.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  12. Gavin PG, Mullaney JA, Loo D, Cao KL, Gottlieb PA, Hill MM, Zipris D, Hamilton-Williams EE. Intestinal Metaproteomics Reveals Host-Microbiota Interactions in Subjects at Risk for Type 1 Diabetes. Diabetes Care. 2018 10; 41(10):2178-2186. PMID: 30100563.
    Citations: 24     Fields:    Translation:Humans
  13. Mullaney JA, Stephens JE, Costello ME, Fong C, Geeling BE, Gavin PG, Wright CM, Spector TD, Brown MA, Hamilton-Williams EE. Correction to: Type 1 diabetes susceptibility alleles are associated with distinct alterations in the gut microbiota. Microbiome. 2018 03 20; 6(1):51. PMID: 29558994.
    Citations: 2     Fields:    
  14. Mullaney JA, Stephens JE, Costello ME, Fong C, Geeling BE, Gavin PG, Wright CM, Spector TD, Brown MA, Hamilton-Williams EE. Type 1 diabetes susceptibility alleles are associated with distinct alterations in the gut microbiota. Microbiome. 2018 02 17; 6(1):35. PMID: 29454391.
    Citations: 18     Fields:    Translation:HumansAnimalsCells
  15. Kim SR, Gavin PG, Pogue-Geile K. Prognostic Role of Immunoglobulin G Fragment C Receptor Polymorphisms in Solid Tumors-Reply. JAMA Oncol. 2018 01 01; 4(1):132-133. PMID: 28973296.
    Citations:    Fields:    Translation:Humans
  16. Kim SR, Song N, Yothers G, Gavin PG, Allegra CJ, Paik S, Pogue-Geile KL. Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology). Br J Cancer. 2018 03 06; 118(5):629-633. PMID: 29241223.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  17. Gavin PG, Song N, Kim SR, Lipchik C, Johnson NL, Bandos H, Finnigan M, Rastogi P, Fehrenbacher L, Mamounas EP, Swain SM, Wickerham DL, Geyer CE, Jeong JH, Costantino JP, Wolmark N, Paik S, Pogue-Geile KL. Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial. JAMA Oncol. 2017 Mar 01; 3(3):335-341. PMID: 27812689.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  18. Song N, Pogue-Geile KL, Gavin PG, Yothers G, Kim SR, Johnson NL, Lipchik C, Allegra CJ, Petrelli NJ, O'Connell MJ, Wolmark N, Paik S. Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial. JAMA Oncol. 2016 Sep 01; 2(9):1162-9. PMID: 27270348.
    Citations: 44     Fields:    Translation:HumansCells
  19. Sheridan-Pereira M, Murphy J, Sloan J, Crispino G, Leahy A, Corcoran JD, Dempsey E, Elnazir B, Gavin P, Sharif F, Gul R, Satas S, Murphy J, Gormally S, Shanaa I, Waldron D, Mc Mahon P, Carson J, Blanken M, Bont L, Paes B. Respiratory Syncytial Virus Preterm (32-36 Completed Weeks of Gestation) Risk Estimation Measure for RSV Hospitalization in Ireland: A Prospective Study. Pediatr Infect Dis J. 2016 Jan; 35(1):19-24. PMID: 26379160.
    Citations: 8     Fields:    Translation:HumansCells
  20. Gavin PG, Song N, Kim SR, Pogue-Geile KL, Paik S. Immune Signature to Predict Trastuzumab Benefit: Potential and Pitfalls. J Clin Oncol. 2015 Nov 01; 33(31):3671-2. PMID: 26282639.
    Citations: 1     Fields:    Translation:Humans
  21. Pogue-Geile KL, Song N, Jeong JH, Gavin PG, Kim SR, Blackmon NL, Finnigan M, Rastogi P, Fehrenbacher L, Mamounas EP, Swain SM, Wickerham DL, Geyer CE, Costantino JP, Wolmark N, Paik S. Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. J Clin Oncol. 2015 Apr 20; 33(12):1340-7. PMID: 25559813.
    Citations: 30     Fields:    Translation:Humans
  22. Chera BS, Eisbruch A, Murphy BA, Ridge JA, Gavin P, Reeve BB, Bruner DW, Movsas B. Recommended patient-reported core set of symptoms to measure in head and neck cancer treatment trials. J Natl Cancer Inst. 2014 Jul; 106(7). PMID: 25006189.
    Citations: 16     Fields:    Translation:Humans
  23. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014 Jun 20; 32(18):1941-67. PMID: 24733808.
    Citations: 294     Fields:    Translation:Humans
  24. Pogue-Geile KL, Kim C, Jeong JH, Tanaka N, Bandos H, Gavin PG, Fumagalli D, Goldstein LC, Sneige N, Burandt E, Taniyama Y, Bohn OL, Lee A, Kim SI, Reilly ML, Remillard MY, Blackmon NL, Kim SR, Horne ZD, Rastogi P, Fehrenbacher L, Romond EH, Swain SM, Mamounas EP, Wickerham DL, Geyer CE, Costantino JP, Wolmark N, Paik S. Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. J Natl Cancer Inst. 2013 Dec 04; 105(23):1782-8. PMID: 24262440.
    Citations: 40     Fields:    Translation:Humans
  25. Pogue-Geile K, Yothers G, Taniyama Y, Tanaka N, Gavin P, Colangelo L, Blackmon N, Lipchik C, Kim SR, Sharif S, Allegra C, Petrelli N, O'Connell MJ, Wolmark N, Paik S. Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08. J Natl Cancer Inst. 2013 Jul 03; 105(13):989-92. PMID: 23821759.
    Citations: 19     Fields:    Translation:HumansCells
  26. Gavin PG, Paik S, Yothers G, Pogue-Geile KL. Colon cancer mutation: prognosis/prediction--response. Clin Cancer Res. 2013 Mar 01; 19(5):1301. PMID: 23396048.
    Citations: 6     Fields:    Translation:Humans
  27. Gavin PG, Colangelo LH, Fumagalli D, Tanaka N, Remillard MY, Yothers G, Kim C, Taniyama Y, Kim SI, Choi HJ, Blackmon NL, Lipchik C, Petrelli NJ, O'Connell MJ, Wolmark N, Paik S, Pogue-Geile KL. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res. 2012 Dec 01; 18(23):6531-41. PMID: 23045248.
    Citations: 104     Fields:    Translation:HumansCells
  28. Fumagalli D, Gavin PG, Taniyama Y, Kim SI, Choi HJ, Paik S, Pogue-Geile KL. A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer. 2010 Mar 16; 10:101. PMID: 20233444.
    Citations: 58     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Gavin's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (150)
Explore
_
Co-Authors (1)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.